Flashback Foreword: Adjuvant Interferon α-2b for High-Risk Melanoma
Authors: Gary K. Schwartz
Journal: Journal of Clinical Oncology (2023)

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. January 17, 2023 ARTICLE CITATION DOI: 10.1200/JCO.22.02354 Journal of Clinical Oncology - published online before print January 17, 2023 PMID: 36649674 Flashback Foreword: Adjuvant Interferon α-2b for High-Risk Melanoma Gary K. Schwartz, MD1,2xGary K. SchwartzSearch for articles by this author Show More 1Columbia University, New York, NY2Associate Editor, Journal of Clinical Oncology, Alexandria, VA https://doi.org/10.1200/JCO.22.02354 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYIn 1996, Kirkwood et al1 published the first study to show a benefit for any immunotherapy (in this case, interferon α-2b) in the adjuvant setting for resected cutaneous melanoma. Although controversial, it became a part of the standard of care in the treatment of this disease for many years.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Adjuvant Interferon α-2b for High-Risk MelanomaThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Gary K. SchwartzThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Stock and Other Ownership Interests: GenCirq, Bionaut Labs, January TherapeuticsConsulting or Advisory Role: Bionaut Labs, Ellipses Pharma, Gencirq, Epizyme, Array BioPharma, Apexigen, Oncogenuity, OnCusp Therapeutics, Concarlo, Shanghai Pharma, Astex Pharmaceuticals, January Therapeutics, Sellas Life Sciences, PureTech, AADi, Kirilys TherapeuticsResearch Funding: Astex Pharmaceuticals, Incyte (Inst), Calithera Biosciences (Inst), Lilly (Inst), Daiichi Sankyo (Inst), Fortress Biotech (Inst), Karyopharm Therapeutics (Inst), Oxford BioTherapeutics (Inst), Astex Pharmaceuticals (Inst), TopAlliance BioSciences Inc (Inst), Adaptimmune (Inst), SpringWorks Therapeutics (Inst), TRACON Pharma (Inst)Patents, Royalties, Other Intellectual Property: Companion diagnostics for CD4 inhibitors (Inst), patent granted to develop a new technology called PNAs for cancer therapyTravel, Accommodations, Expenses: Array BioPharma, EpizymeNo other potential conflicts of interest were reported. Companion Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684